| Literature DB >> 15922858 |
Jia-Lin Yang1, Xian-Jun Qu, Pamela J Russell, David Goldstein.
Abstract
Interferon-alpha (IFNalpha) treatment is associated with up-regulation of epidermal growth factor receptor (HER1/EGFR) expression and marked growth inhibition while maintaining the sensitivity of the target colon cancer cells to epidermal growth factor (Gut 2004;53:123). We aimed to determine the effect of combining IFNalpha and Erlotinib (an HER1/EGFR inhibitor) on colon cancer cell line growth. Crystal-violet staining and flow cytometry were used to assess cell proliferation and expression of HER1/EGFR. IFNalpha pre-treatment followed by a combination of IFNalpha plus Erlotinib significantly enhanced the sensitivity of 7/9 of colon cancer cell lines by 7-43%. This approach may have clinical implications for improving treatment based on targeting of HER1/EGFR.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15922858 DOI： 10.1016/j.canlet.2004.11.041
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679